Bluejay Diagnostics, Inc.
BJDXHealthcareNASDAQMedical Devices
Scan Results
Daily timeframeHeadquartered within the healthcare sector, Bluejay Diagnostics, Inc. focuses on Medical Devices services and products. Bluejay Diagnostics, Inc. operates as a medical diagnostics company. Valued at $1.2M, BJDX is a micro-cap name in its sector. It offers Symphony technology platform which consists of an analyzer and single-use protein detection cartridges that are designed to provide measurements of key diagnostic biomarkers found in blood; and Symphony analyzer used to orchestrate sample processing of whole blood, plasma, serum, etc., biomarker isolation, and immunoassay preparation using non-contact centrifugal force.
Market Cap
$1.2M
Beta
0.88
P/E (TTM)
—
P/E (Fwd)
-3.63
EPS (TTM)
$-3.74
EPS (Fwd)
$-0.32
ROE
-171.6%
ROA
-79.7%
Cash
$3.7M
Total Debt
$105,328
Free CF
-$4.1M
52W Change
-81.4%
Annual Financials
Cash vs Debt
Where BJDX stands vs its 150-day and 200-day moving averages
As of the July 15, 2026 close, BJDX finished 51.74% below its 150-day moving average ($2.59) and 67.45% below its 200-day moving average ($3.84). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is BJDX overbought or oversold?
At the July 15, 2026 close, BJDX's RSI(14) was 18.5, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Bluejay Diagnostics, Inc. holds $3.7M in cash against $105K in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. The company is burning cash, with free cash flow at -$4.1M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. ROE of -171.6% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has pulled back from $249K (2022) to $0 (2025), a 100% decline worth watching.
The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing BJDX.